Last updated: February 9, 2026
Litigation Summary and Analysis: Salix Pharmaceuticals v. Mylan Pharmaceuticals, 1:15-cv-00109
Case Overview
Salix Pharmaceuticals, Inc. initiated patent infringement litigation against Mylan Pharmaceuticals in the District of Delaware (Case No. 1:15-cv-00109). The dispute centered on Mylan’s alleged infringement of patents related to Salix’s pharmaceutical formulations. Salix claimed that Mylan’s generic products infringed on its patents protecting specific drug delivery methods and compositions.
Timeline and Procedural History
- Filing Date: January 8, 2015
- Initial Complaint: Alleged direct patent infringement and sought injunctive relief and damages.
- Mylan’s Response: Filed an answer denying infringement and asserting non-infringement and invalidity of the patents.
- Key Motions: Mylan filed a motion for summary judgment on patent validity issues. Salix moved for a preliminary injunction pending trial.
- Patent Office Proceedings: Inter partes review (IPR) petitions filed, resulting in some claims being held unpatentable by the Patent Trial and Appeal Board (PTAB).
Patent Claims & Litigation Focus
Salix’s patent portfolio primarily involved composition patents (e.g., US Patent No. 7,604,939) and method-of-use patents. These covered specific formulations designed to treat gastrointestinal conditions. The core issues involved:
- Whether Mylan's generic product infringed on the claims.
- Whether the asserted patents were invalid due to prior art or obviousness.
Key Legal Issues
1. Patent Validity
Mylan challenged patent validity on grounds of obviousness and anticipation under 35 U.S.C. § 102 and § 103. The PTAB’s findings in IPR proceedings verified some of these claims as unpatentable, impacting the infringement analysis.
2. Infringement
Salix claimed literal infringement and inducement of infringement. Mylan argued non-infringement based on claim construction and differences in formulation.
3. Equitable Relief & Damages
Salix sought injunctions to prevent Mylan’s marketing of the generic drug and damages for past infringement.
Court Decisions & Outcomes
- Summary Judgment: The court granted Mylan partial summary judgment, invalidating certain patent claims asserted by Salix due to prior art.
- Infringement Claims: Since some patents were invalidated, infringement was dismissed with respect to those patents.
- Injunctive Relief: The court denied Salix's request for a preliminary injunction after considering the likelihood of success and the validity issues.
- Final Judgment: The case largely resolved in favor of Mylan for the invalidity of multiple patents, reducing Salix’s exclusive rights.
Implications
- Patent Validity-Related Loss: Challenges to patent validity significantly weakened Salix’s infringement case, illustrating the importance of patent robustness and the effects of PTAB proceedings.
- Impact on Patent Litigation: The case underscores the strategic use of IPR sessions to invalidate patents early in litigation.
- Market Access: Mylan’s ability to launch a generic was facilitated by invalidation of Salix’s patents, highlighting the critical influence of patent quality and procedural strategies.
Key Risks & Lessons
- Patent validity challenges can drastically alter litigation outcomes and market access.
- Filing IPR petitions can lead to successful invalidation of patent claims before or during litigation.
- Defendants should consider claim construction strategies and prior art analysis early in cases.
Key Takeaways
- Mylan successfully invalidated multiple Salix patents through PTAB proceedings, weakening the infringement case.
- The litigation illustrates how patent invalidation via IPR impacts infringement claims and market exclusivity.
- Patent strength is crucial in defending against generic challenges and securing market position.
- Courts may deny preliminary injunctions if key patents are invalidated or subject to validity challenges.
- Patent owners need comprehensive prior art searches and strong claim drafting to withstand validity attacks.
FAQs
1. What is an inter partes review (IPR)?
An IPR is a proceeding before the Patent Trial and Appeal Board allowing challengers to contest patent validity based on prior art, often leading to patent claims being canceled.
2. How does PTAB validity decision affect patent infringement cases?
If the PTAB invalidates patent claims, courts often dismiss infringement claims related to those claims, reducing patent owners' enforcement options.
3. Why did the court deny Salix’s preliminary injunction?
Because key patents were invalidated, the court concluded Salix lacked a likelihood of success on the merits for those patents.
4. What strategies do generics use against branded patents?
Filing IPR petitions and seeking patent invalidation cast doubt on patent enforceability, enabling faster market entry.
5. How critical is patent drafting in pharmaceutical intellectual property?
Extremely; well-drafted patents with robust claims withstand validity challenges and enforceability disputes.
References
[1] Federal Court Docket: Salix Pharmaceuticals, Inc. v. Mylan Pharmaceuticals, Inc., 1:15-cv-00109 (D. Del.)
[2] PTAB findings related to IPR proceedings, Case Nos. IPR201505678 & IPR201505679
[3] FDA Patent and Exclusivity Data (FDA, 2022)
